LEXINGTON, Mass., October 21, 2021–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a convention name at 8:00 a.m. ET Thursday, October 28, 2021 to report monetary outcomes for the quarter ended September 30, 2021 and talk about latest enterprise highlights.
The dial-in numbers are (866) 211-4098 for home callers and (647) 689-6613 for worldwide callers. The Convention ID quantity is 8891298. A reside webcast of the convention name will even be obtainable on the Traders & Media web page of the corporate’s company web site at https://ir.aldeyra.com.
After the reside webcast, the occasion will stay archived on the Aldeyra Therapeutics web site for 90 days.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a biotechnology firm growing novel immune-modulating therapies to deal with ocular and systemic illnesses. Two of the corporate’s lead product candidates, reproxalap and ADX-629, goal RASP, that are pre-cytokine, systems-based mediators of irritation. Reproxalap is being evaluated in Section 3 scientific trials in sufferers with dry eye illness and allergic conjunctivitis. The corporate’s scientific pipeline additionally consists of ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Section 3 testing for the prevention of proliferative vitreoretinopathy. For extra data, go to https://www.aldeyra.com/ and comply with us on LinkedIn, Fb, and Twitter.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20211021005142/en/
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
Investor & Media Contact:
Sharon Merrill Associates, Inc.